Video Experimental Relacionado
Updated: Aug 16, 2026
11:40
Quantitative Autonomic Testing
Published on: July 19, 2011
El potente efecto presurizador de la fenilpropanolamina en pacientes con deterioro autónomo
JAMA
|July 10, 1987
Resumen
El clorhidrato de fenilpropanolamina aumenta efectivamente la presión arterial en pacientes con insuficiencia autónoma y hipotensión ortostática. Este agente simpatomimético proporciona un efecto presor significativo sin alterar la frecuencia cardíaca.
Área de la Ciencia:
- Farmacología Farmacología.
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Neurología Neurología.
Sus antecedentes:
- La hipotensión ortostática y la insuficiencia autónoma son condiciones caracterizadas por una caída significativa en la presión arterial al levantarse.
- El clorhidrato de fenilpropanolamina es un agente simpatomimético con propiedades vasoconstrictoras conocidas.
Objetivo del estudio:
- Para evaluar el efecto presor del clorhidrato de fenilpropanolamina en pacientes que sufren de insuficiencia autónoma y hipotensión ortostática.
- Para determinar la dosis y la duración de la respuesta del presor al clorhidrato de fenilpropanolamina.
Principales métodos:
- Un estudio en el que participaron 14 pacientes diagnosticados con insuficiencia autónoma y hipotensión ortostática.
- Monitoreo continuo de la presión arterial utilizando un dispositivo automatizado cada cinco minutos mientras los pacientes estaban en posición sentada.
- Administración oral de clorhidrato de fenilpropanolamina en dosis de 25 mg y 12,5 mg.
Principales resultados:
- La administración oral de 25 mg de clorhidrato de fenilpropanolamina dio lugar a aumentos significativos en la presión arterial sistólica (32 mm Hg), diastólica (15 mm Hg) y media (21 mm Hg).
- El efecto presor se observó dentro de los 60 minutos y persistió hasta 105 minutos después de la administración.
- Una dosis más baja de 12,5 mg también produjo un aumento significativo en la presión arterial en un subconjunto de pacientes.
- No se registraron cambios significativos en la frecuencia cardíaca durante el estudio.
Conclusiones:
- El clorhidrato de fenilpropanolamina (25 mg) provoca una potente respuesta presor en pacientes con hipotensión ortostática.
- Los médicos deben ser conscientes de la posibilidad de hipertensión significativa después de la administración de este agente.
- El estudio destaca la eficacia del clorhidrato de fenilpropanolamina en el control de la presión arterial en poblaciones específicas de pacientes.
Más Videos Relacionados
06:30Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
Published on: September 11, 2018
08:41Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
Published on: June 3, 2019
Videos de Conceptos Relacionados
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...